High Velocity Therapy in Level II and Level III NICUs
Review benefits of high velocity therapy use in Level II and Level III NICUs.
- Detail the mechanisms of action of high velocity therapy.
- Describe the correct patient interface and clinical applications of high velocity therapy.
- Review published clinical trial data which differentiates high velocity therapy from high flow nasal cannula.
- Review potential economic and resource utilization benefits of high velocity therapy use in Level II & Level III NICUs.
Michael C. McQueen MD, MBA, FAAP, has over 28 years of clinical and leadership experience. He has served as Regional Medical Director for Envision Healthcare, Medical Director of the NICU at Phoenix Children’s Hospital, as well as several NICUs within the Banner Healthcare System in Phoenix. He has also served as Regional President for Pediatrix Medical Group, and President of Obstetrix Medical Group. Dr. McQueen completed his Pediatric Residency at Phoenix Children’s Hospital / Maricopa Medical Center in Phoenix, AZ, and his Neonatal-Perinatal Medicine Fellowship at the University of Vermont, Burlington, VT. His recent contributions on High-Velocity Nasal Insufflation respiratory support in neonates can be found in J Pulm Respir Med (2014), J Health Economics and Outcomes Research (2015), and J Perinatology (2017). Dr. McQueen is currently Vice President of Medical Affairs at Vapotherm, Inc.